Physician profile
Michael Barmach
NPI 1457475584
$2,852.03
in general payments reported to CMS, 2019-2025
24 companies · $247 in 2025
The $247 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $893 · 2020: $161 · 2021: $175 · 2022: $379 · 2023: $508 · 2024: $490 · 2025: $247.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,244.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,243.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $458.57 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $394.35 | 2019-2025 | Evenity, Prolia, Repatha |
| Abbvie INC. | $380.76 | 2021-2025 | Vraylar |
| Novo Nordisk INC | $372.44 | 2019-2025 | Rybelsus, Ozempic |
| Lilly USA, LLC | $278.61 | 2019-2025 | Zepbound, Jardiance, Mounjaro |
| Pfizer INC. | $160.77 | 2019-2025 | |
| Glaxosmithkline, LLC. | $151.83 | 2019-2025 | Trelegy Ellipta, Arexvy, Bexsero |
| Janssen Pharmaceuticals, INC | $118.00 | 2019 | |
| Merck Sharp & Dohme LLC | $102.62 | 2019-2022 | |
| Abbott Laboratories | $101.90 | 2022-2023 | Freestyle Libre 2 |
| Astellas Pharma US INC | $46.69 | 2019 | |
| Amarin Pharma, INC. | $36.95 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $36.31 | 2022-2023 | Rexulti |
| Exact Sciences Corporation | $29.75 | 2024 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.82 | 2019-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $23.61 | 2021 | |
| Lundbeck LLC | $20.32 | 2023 | Rexulti |
| Vertos Medical, INC. | $19.64 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $17.27 | 2024 | Eliquis |
| Sanofi Pasteur INC. | $16.87 | 2019 | |
| Dynavax Technologies Corporation | $15.29 | 2023 | Heplisav-B |
| Takeda Pharmaceuticals U.S.A., INC. | $15.12 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.03 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $12.51 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Barmach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.